SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. The number of COVID-19 cases and deaths in India has risen steeply, and a SARS-CoV-2 variant, B.1.617, is believed to be responsible f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Markus, Hofmann-Winkler, Heike, Krüger, Nadine, Kempf, Amy, Nehlmeier, Inga, Graichen, Luise, Arora, Prerna, Sidarovich, Anzhalika, Moldenhauer, Anna-Sophie, Winkler, Martin S., Schulz, Sebastian, Jäck, Hans-Martin, Stankov, Metodi V., Behrens, Georg M.N., Pöhlmann, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238662/
https://www.ncbi.nlm.nih.gov/pubmed/34270919
http://dx.doi.org/10.1016/j.celrep.2021.109415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238662/
https://www.ncbi.nlm.nih.gov/pubmed/34270919
http://dx.doi.org/10.1016/j.celrep.2021.109415

Ejemplares similares